Cargando…
Curcumin: Useful add-on for Rheumatic Diseases?
Plant-derived nutraceuticals are proposed as new key instruments to represent a profound “back to basics” shift in medical treatment. Data accumulated over the past ten years suggest that curcumin, the major active compound of the turmeric plant, has anti-inflammatory properties. It has yet to be de...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143911/ https://www.ncbi.nlm.nih.gov/pubmed/35629033 http://dx.doi.org/10.3390/jcm11102908 |
_version_ | 1784715922029674496 |
---|---|
author | Tomaras, Stylianos Keyßer, Gernot Feist, Eugen |
author_facet | Tomaras, Stylianos Keyßer, Gernot Feist, Eugen |
author_sort | Tomaras, Stylianos |
collection | PubMed |
description | Plant-derived nutraceuticals are proposed as new key instruments to represent a profound “back to basics” shift in medical treatment. Data accumulated over the past ten years suggest that curcumin, the major active compound of the turmeric plant, has anti-inflammatory properties. It has yet to be determined whether the anti-inflammatory profile of curcumin is potent enough to justify the application of this substance as a nutritional supplement for patients with rheumatic diseases. To address this question, the most relevant in vitro studies that investigate the mechanism of action of curcumin were reviewed in this article. In addition, a total of 18 animal and human trials were evaluated. The pleiotropic, anti-inflammatory and immunomodulatory effects of curcumin were observed in animal studies. In addition, human trials demonstrated promising findings. In these studies, curcumin was able to reduce the expression of proinflammatory cytokines, lower the level of the C-reactive protein and improve clinical parameters. A limiting factor of the application of curcumin is the inconsistent bioavailability of the substance. Therefore, new formulations have been developed to improve the pharmacodynamic profile of curcumin. The future acceptance of the substance is dependent on new controlled clinical trials with a standardised formulation of curcumin administered as well as standard of care. |
format | Online Article Text |
id | pubmed-9143911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91439112022-05-29 Curcumin: Useful add-on for Rheumatic Diseases? Tomaras, Stylianos Keyßer, Gernot Feist, Eugen J Clin Med Review Plant-derived nutraceuticals are proposed as new key instruments to represent a profound “back to basics” shift in medical treatment. Data accumulated over the past ten years suggest that curcumin, the major active compound of the turmeric plant, has anti-inflammatory properties. It has yet to be determined whether the anti-inflammatory profile of curcumin is potent enough to justify the application of this substance as a nutritional supplement for patients with rheumatic diseases. To address this question, the most relevant in vitro studies that investigate the mechanism of action of curcumin were reviewed in this article. In addition, a total of 18 animal and human trials were evaluated. The pleiotropic, anti-inflammatory and immunomodulatory effects of curcumin were observed in animal studies. In addition, human trials demonstrated promising findings. In these studies, curcumin was able to reduce the expression of proinflammatory cytokines, lower the level of the C-reactive protein and improve clinical parameters. A limiting factor of the application of curcumin is the inconsistent bioavailability of the substance. Therefore, new formulations have been developed to improve the pharmacodynamic profile of curcumin. The future acceptance of the substance is dependent on new controlled clinical trials with a standardised formulation of curcumin administered as well as standard of care. MDPI 2022-05-20 /pmc/articles/PMC9143911/ /pubmed/35629033 http://dx.doi.org/10.3390/jcm11102908 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tomaras, Stylianos Keyßer, Gernot Feist, Eugen Curcumin: Useful add-on for Rheumatic Diseases? |
title | Curcumin: Useful add-on for Rheumatic Diseases? |
title_full | Curcumin: Useful add-on for Rheumatic Diseases? |
title_fullStr | Curcumin: Useful add-on for Rheumatic Diseases? |
title_full_unstemmed | Curcumin: Useful add-on for Rheumatic Diseases? |
title_short | Curcumin: Useful add-on for Rheumatic Diseases? |
title_sort | curcumin: useful add-on for rheumatic diseases? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143911/ https://www.ncbi.nlm.nih.gov/pubmed/35629033 http://dx.doi.org/10.3390/jcm11102908 |
work_keys_str_mv | AT tomarasstylianos curcuminusefuladdonforrheumaticdiseases AT keyßergernot curcuminusefuladdonforrheumaticdiseases AT feisteugen curcuminusefuladdonforrheumaticdiseases |